ERBB2 and non-small cell lung carcinoma: Furthermore, a phase Ib/II trial (NCT05482568) is currently recruiting to assess SHR-A1811 in combination with pyrotinib or SHR-1316, an anti-PD-L1 antibody, in patients with advanced HER2-altered NSCLC (143).